The opportunities of mining historical and collective data in drug discovery

Drug Discovery Today

Volumn 20, Issue 4, 2015, Pages 422-434

  Wassermann, Anne Mai ^a   Lounkine, Eugen ^a   Davies, John W ^a   Glick, Meir ^a   Camargo, L Miguel ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ANIMAL; CHEMICAL DATABASE; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DATA MINING; DRUG DATABASE; DRUG DEVELOPMENT; DRUG EFFECTS; HISTORY; HUMAN; PROCEDURES; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; COMPUTER SIMULATION; DATA MINING; DATABASES, CHEMICAL; DATABASES, PHARMACEUTICAL; DRUG DISCOVERY; HISTORY, 21ST CENTURY; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84939958419     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.11.004     Document Type: Review

References (97)

1. Y. Wang PubChem BioAssay: 2014 update Nucleic Acids Res. 42 2014 D1075 D1082
2. S. Muresan Making every SAR point count: the development of Chemistry Connect for the large-scale integration of structure and bioactivity data Drug Discov. Today 16 2011 1019 1030
3. W. Zheng Phenotypic screens as a renewed approach for drug discovery Drug Discov. Today 18 2013 1067 1073
4. R.H. Shoemaker The NCI60 human tumour cell line anticancer drug screen Nat. Rev. Cancer 6 2006 813 823
5. M. Monga, and E.A. Sausville Developmental therapeutics program at the NCI: molecular target and drug discovery process Leukemia 16 2002 520 526
6. K.D. Paull Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm J. Natl. Cancer Inst. 81 1989 1088 1092
7. D.W. Zaharevitz COMPARE: a web accessible tool for investigating mechanisms of cell growth inhibition J. Mol. Graph. Model. 20 2002 297 303
8. J.N. Weinstein Neural computing in cancer drug development: predicting mechanism of action Science 258 1992 447 451
9. T. Cheng Identifying compound-target associations by combining bioactivity profile similarity search and public databases mining J. Chem. Inf. Model. 51 2011 2440 2448
10. J. Barretina The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Nature 483 2012 603 607
11. M.J. Garnett Systematic identification of genomic markers of drug sensitivity in cancer cells Nature 483 2012 570 575
12. F.J. King Pathway reporter assays reveal small molecule mechanisms of action J. Assoc. Lab. Autom. 14 2009 374 382
13. C.M. Krejsa Predicting ADME properties and side effects: the BioPrint approach Curr. Opin. Drug Discov. Dev. 6 2003 470 480
14. A.F. Fliri Biological spectra analysis: linking biological activity profiles to molecular structure Proc. Natl. Acad. Sci. U. S. A. 102 2005 261 266
15. A.F. Fliri Biospectra analysis: model proteome characterizations for linking molecular structure and biological response J. Med. Chem. 48 2005 6918 6925
16. A.F. Fliri Analysis of drug-induced effect patterns to link structure and side effects of medicines Nat. Chem. Biol. 1 2005 389 397
17. D. Plouffe In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen Proc. Natl. Acad. Sci. U. S. A. 105 2008 9059 9064
18. P.M. Petrone Rethinking molecular similarity: comparing compounds on the basis of biological activity ACS Chem. Biol. 7 2012 1399 1409
19. A.M. Wassermann A screening pattern recognition method finds new and divergent targets for drugs and natural products ACS Chem. Biol. 9 2014 1622 1631
20. R. Edgar Gene Expression Omnibus: NCBI gene expression and hybridization array data repository Nucleic Acids Res. 30 2002 207 210
21. H. Parkinson ArrayExpress - a public database of microarray experiments and gene expression profiles Nucleic Acids Res. 35 2007 D747 D750
22. G. Sherlock The Stanford Microarray Database Nucleic Acids Res. 29 2001 152 155
23. Y.-A. Lin Methodologies for extracting functional pharmacogenomic experiments from international repository AMIA Annu. Symp. Proc. 2007 463 467
24. J. Lamb The Connectivity Map: a new tool for biomedical research Nat. Rev. Cancer 7 2007 54 60
25. J. Lamb The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease Science 313 2006 1929 1935
26. H. Hieronymus Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators Cancer Cell 10 2006 321 330
27. T. Montero-Melendez Gene expression signature-based approach identifies a pro-resolving mechanism of action for histone deacetylase inhibitors Cell Death Differ. 20 2013 567 575
28. T.R. Hughes Functional discovery via a compendium of expression profiles Cell 102 2000 109 126
29. T.A. Addona A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease Nat. Biotechnol. 29 2011 635 643
30. R. Hüttenhain Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics Sci. Transl. Med. 4 2012 142ra94
31. E.L. Berg Chemical target and pathway toxicity mechanisms defined in primary human cell systems J. Pharmacol. Toxicol. Methods 61 2010 3 15
32. E.J. Kunkel An integrative biology approach for analysis of drug action in models of human vascular inflammation FASEB J. 18 2004 1279 1281
33. K.A. Houck Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems J. Biomol. Screen. 14 2009 1054 1066
34. E.L. Berg Building predictive models for mechanism-of-action classification from phenotypic assay data sets J. Biomol. Screen. 18 2013 1260 1269
35. J.E. Bandow Proteomic approach to understanding antibiotic action Antimicrob. Agents Chemother. 47 2003 948 955
36. F. Reisen Benchmarking of multivariate similarity measures for high-content screening fingerprints in phenotypic drug discovery J. Biomol. Screen. 18 2013 1284 1297
37. H. Al-Ali Chemical interrogation of the neuronal kinome using a primary cell-based screening assay ACS Chem. Biol. 8 2013 1027 1036
38. D.L. Towne Development of a high-content screening assay panel to accelerate mechanism of action studies for oncology research J. Biomol. Screen. 17 2012 1005 1017
39. C.J. Schulze Function-first lead discovery: mode of action profiling of natural product libraries using image-based screening Chem. Biol. 20 2013 285 295
40. C.L. Adams Compound classification using image-based cellular phenotypes Methods Enzymol. 414 2006 440 468
41. Z.E. Perlman Multidimensional drug profiling by automated microscopy Science 306 2004 1194 1198
42. D.W. Young Integrating high-content screening and ligand-target prediction to identify mechanism of action Nat. Chem. Biol. 4 2008 59 68
43. M. Campillos Drug target identification using side-effect similarity Science 321 2008 263 266
44. L.M. Kauvar Predicting ligand binding to proteins by affinity fingerprinting Chem. Biol. 2 1995 107 118
45. J.N. Weinstein An information-intensive approach to the molecular pharmacology of cancer Science 275 1997 343 349
46. K. Wosikowski Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns J. Natl. Cancer Inst. 89 1997 1505 1515
47. M. Sirota Discovery and preclinical validation of drug indications using compendia of public gene expression data Sci. Transl. Med. 3 2011 96ra77
48. D. Cavalla Predictive methods in drug repurposing: gold mine or just a bigger haystack? Drug Discov. Today 18 2013 523 532
49. Y. Ishimatsu-Tsuji Identification of novel hair-growth inducers by means of connectivity mapping FASEB J. 24 2010 1489 1496
50. X.A. Qu, and D.K. Rajpal Applications of Connectivity Map in drug discovery and development Drug Discov. Today 17 2012 1289 1298
51. D.G. McArt Connectivity mapping for candidate therapeutics identification using next generation sequencing RNA-Seq data PLOS ONE 8 2013 e66902
52. D.C. Hassane Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways Blood 116 2010 5983 5990
53. H. Sun Classification of scaffold-hopping approaches Drug Discov. Today 17 2012 310 324
54. K.D. Paull Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data Cancer Res. 52 1992 3892 3900
55. D.C. Hassane Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data Blood 111 2008 5654 5662
56. A.M. Wassermann Bioturbo similarity searching: combining chemical and biological similarity to discover structurally diverse bioactive molecules J. Chem. Inf. Model. 53 2013 692 703
57. A.M. Wassermann Efficient search of chemical space: navigating from fragments to structurally diverse chemotypes J. Med. Chem. 56 2013 8879 8891
58. D. Muthas, and S. Boyer Exploiting pharmacological similarity to identify safety concerns - listen to what the data tells you Mol. Inform. 32 2013 37 45
59. D.J. Dix The ToxCast program for prioritizing toxicity testing of environmental chemicals Toxicol. Sci. 95 2007 5 12
60. R. Kavlock Update on EPA's ToxCast program: providing high throughput decision support tools for chemical risk management Chem. Res. Toxicol. 25 2012 1287 1302
61. N.S. Sipes Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays Chem. Res. Toxicol. 26 2013 878 895
62. F. Shah, and N. Greene Analysis of Pfizer compounds in EPA's ToxCast chemicals-assay space Chem. Res. Toxicol. 27 2014 86 98
63. R.S. Thomas A comprehensive statistical analysis of predicting in vivo hazard using high-throughput in vitro screening Toxicol. Sci. 128 2012 398 417
64. A.J. Olaharski Identification of a kinase profile that predicts chromosome damage induced by small molecule kinase inhibitors PLoS Comput. Biol. 5 2009 e1000446
65. T. Uehara The Japanese toxicogenomics project: application of toxicogenomics Mol. Nutr. Food Res. 54 2010 218 227
66. D.C. Swinney, and J. Anthony How were new medicines discovered? Nat Rev. Drug Discov. 10 2011 507 519
67. A. Wolf-Yadlin Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks Proc. Natl. Acad. Sci. U. S. A. 104 2007 5860 5865
68. A. Nita-Lazar Quantitative phosphoproteomics by mass spectrometry: past, present, and future Proteomics 8 2008 4433 4443
69. M. Niepel Profiles of basal and stimulated receptor signaling networks predict drug response in breast cancer lines Sci. Signal. 6 2013 ra84
70. D. Rogers, and M. Hahn Extended-connectivity fingerprints J. Chem. Inf. Model. 50 2010 742 754
71. K.P. Seiler ChemBank: a small-molecule screening and cheminformatics resource database Nucleic Acids Res. 36 2008 D351 D359
72. A. Gaulton ChEMBL: a large-scale bioactivity database for drug discovery Nucleic Acids Res. 40 2012 D1100 D1107
73. V.R. Polyakov Enrichment analysis for discovering biological associations in phenotypic screens J. Chem. Inf. Model. 54 2014 377 386
74. X. Liu, and M. Campillos Unveiling new biological relationships using shared hits of chemical screening assay pairs Bioinformatics 30 2014 i579 i586
75. Y. Zhang, and D. Reinberg Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails Genes Dev. 15 2001 2343 2360
76. E. Reiter, and R.J. Lefkowitz GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling Trends Endocrinol. Metab. 17 2006 159 165
77. M.J. Keiser The chemical basis of pharmacology Biochemistry 49 2010 10267 10276
78. J.A. Blake Gene ontology annotations and resources Nucleic Acids Res. 41 2013 D530 D535
79. S. Chatterjee Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer J. Clin. Invest. 123 2013 1732 1740
80. N. Kumar Receptor tyrosine kinase inhibitors that block replication of influenza a and other viruses Antimicrob. Agents Chemother. 55 2011 5553 5559
81. M. Marti-Solano Integrative knowledge management to enhance pharmaceutical R&D Nat. Rev. Drug Discov. 13 2014 239 240
82. Y. Hu, and J. Bajorath Learning from big data: compounds and targets Drug Discov. Today 19 2014 357 360
83. S.J. Lusher Data-driven medicinal chemistry in the era of big data Drug Discov. Today 19 2014 859 868
84. T.S. Gujral Exploiting polypharmacology for drug target deconvolution Proc. Natl. Acad. Sci. U. S. A. 111 2014 5048 5053
85. F.S. Collins, and L.A. Tabak Policy: NIH plans to enhance reproducibility Nature 505 2014 612 613
86. F. Belleau Bio2RDF: towards a mashup to build bioinformatics knowledge systems J. Biomed. Inform. 41 2008 706 716
87. B. Chen Chem2Bio2RDF: a semantic framework for linking and data mining chemogenomic and systems chemical biology data BMC Bioinformatics 11 2010 255
88. M. Samwald Linked open drug data for pharmaceutical research and development J. Cheminform. 3 2011 19
89. A. De Souza An overview of the challenges in designing, integrating, and delivering BARD: a public chemical-biology resource and query portal for multiple organizations, locations, and disciplines J. Biomol. Screen. 19 2014 614 627
90. A.J. Williams Open PHACTS: semantic interoperability for drug discovery Drug Discov. Today 17 2012 1188 1198
91. U. Visser BioAssay Ontology (BAO): a semantic description of bioassays and high-throughput screening results BMC Bioinformatics 12 2011 257
92. U.D. Vempati Formalization, annotation and analysis of diverse drug and probe screening assay datasets using the BioAssay Ontology (BAO) PLoS ONE 7 2012 e49198
93. C.P. Austin NIH Molecular Libraries Initiative Science 306 2004 1138 1139
94. K. Azzaoui Scientific competency questions as the basis for semantically enriched open pharmacological space development Drug Discov. Today 18 2013 843 852
95. M. Hirode Gene expression profiling in rat liver treated with compounds inducing phospholipidosis Toxicol. Appl. Pharmacol. 229 2008 290 299
96. M. Hirode Gene expression profiling in rat liver treated with compounds inducing elevation of bilirubin Hum. Exp. Toxicol. 28 2009 231 244
97. A.M. Wassermann Composition and applications of focus libraries to phenotypic assays Front. Pharmacol. 2014 10.3389/fphar.2014.00164 e Collection 2014. Review. PubMed PMID: 25104937; PubMedCentral PMCID: PMC4109565.